BACKGROUND: T-cell engagers (TCEs) are transformative immunotherapies with significant potential in treating hematologic malignancies and solid tumors. However, their real-world safety profiles remain inadequately characterized. RESEARCH DESIGN AND METHODS: Using the FDA Adverse Event Reporting System (FAERS) database (October 2019 - September 2024, 8,747,158 reports), we analyzed adverse events (AEs) associated with nine TCEs. Disproportionality analysis identified overreported AEs, with 11,963 unique reports analyzed after deduplication. RESULTS: Blinatumomab was the most reported TCE ( CONCLUSIONS: This study highlights diverse AE profiles of TCEs, providing insights for clinicians to optimize their safe use in practice.